Literature DB >> 21724247

The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.

Luis J Cruz1, Paul J Tacken, Remco Fokkink, Carl G Figdor.   

Abstract

Targeted delivery of nanoparticles (NPs) carrying vaccine components to dendritic cells (DCs) is a promising strategy to initiate antigen-specific immune responses. Improving the interactions between nanoparticle-carried ligands and receptors on DCs is a major challenge. These NPs are generally coated with poly(ethylene glycol) (PEG), to shield non-specific interactions, and antibodies, to facilitate specific delivery to DC surface receptors. We have devised a strategy to covalently link PEG molecules of various chain length (Mw 2000-20000 g/moL) to poly(lactic-co-)glycolic acid (PLGA) NP vaccines. We coated these NPs with various antibodies recognizing the DC-specific receptor DC-SIGN to study the effects of shielding and antibody type on antibody--receptor interactions. Chemical attachment of PEG to the particle surface was followed by detailed zeta potential, DLS and NMR studies, and analyzed by analytical chemistry. Increasing the PEG chain length increased particle size and polydispersity index and reduced the intracellular degradation rate of encapsulated antigens. Binding and uptake of NPs by human DCs was affected by both PEG chain length and antibody type. NPs coated with PEG-3000 had the optimal chain length for antibody--receptor interactions and induction of antigen-specific T-cell responses. Interestingly, clear differences were observed upon targeting distinct epitopes of the same receptor. Binding and uptake of NPs carrying antibodies recognizing the carbohydrate recognition domain of DC-SIGN was enhanced when compared to those carrying antibodies recognizing the receptor's neck region. In conclusion, our data show that PEG chains cannot be extended beyond a certain length for shielding purposes without compromising the efficacy of targeted delivery. Thereby, the implications of our findings are not limited to the future design of nanovaccines specifically targeted to DC-SIGN, but apply to the general design of targeted nanocarriers.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724247     DOI: 10.1016/j.biomaterials.2011.04.082

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  45 in total

Review 1.  Perspectives on Dual Targeting Delivery Systems for Brain Tumors.

Authors:  Huile Gao
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-08       Impact factor: 4.147

Review 2.  Tailored immunity by skin antigen-presenting cells.

Authors:  Clement Levin; Helene Perrin; Behazine Combadiere
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 3.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

4.  Multifunctional nanomedicines: potentials and prospects.

Authors:  Udita Agrawal; Madhu Gupta; Rajesh S Jadon; Rajeev Sharma; S P Vyas
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

Review 5.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

6.  Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.

Authors:  Rajesh Kumar; Paresh C Ray; Dibyadyuti Datta; Geetha P Bansal; Evelina Angov; Nirbhay Kumar
Journal:  Vaccine       Date:  2015-08-20       Impact factor: 3.641

7.  Self-assembled polymeric nanoparticles based on oleic acid-grafted chitosan oligosaccharide: biocompatibility, protein adsorption and cellular uptake.

Authors:  Jing Zhang; Xi Guang Chen; Lu Huang; Jing Tian Han; Xiao Fan Zhang
Journal:  J Mater Sci Mater Med       Date:  2012-05-04       Impact factor: 3.896

8.  Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.

Authors:  Stacey L Demento; Weiguo Cui; Jason M Criscione; Eric Stern; Jacob Tulipan; Susan M Kaech; Tarek M Fahmy
Journal:  Biomaterials       Date:  2012-04-06       Impact factor: 12.479

9.  The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.

Authors:  Yun Hu; Daniel Smith; Evan Frazier; Reece Hoerle; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2016-08-18       Impact factor: 12.479

10.  Display of DNA on Nanoparticles for Targeting Antigen Presenting Cells.

Authors:  Nicholas M Molino; Medea Neek; Jo Anne Tucker; Edward L Nelson; Szu-Wen Wang
Journal:  ACS Biomater Sci Eng       Date:  2017-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.